Dimensional Fund Advisors LP Boosts Position in MaxCyte, Inc. (NASDAQ:MXCT)

Dimensional Fund Advisors LP grew its holdings in shares of MaxCyte, Inc. (NASDAQ:MXCT) by 13.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,010,292 shares of the company’s stock after buying an additional 121,090 shares during the quarter. Dimensional Fund Advisors LP owned 0.96% of MaxCyte worth $3,961,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. PNC Financial Services Group Inc. acquired a new stake in MaxCyte in the 4th quarter valued at $29,000. Salem Investment Counselors Inc. boosted its holdings in MaxCyte by 104.0% in the 1st quarter. Salem Investment Counselors Inc. now owns 56,375 shares of the company’s stock worth $236,000 after acquiring an additional 28,741 shares during the period. China Universal Asset Management Co. Ltd. grew its position in MaxCyte by 65.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 19,884 shares of the company’s stock valued at $83,000 after acquiring an additional 7,898 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of MaxCyte during the first quarter worth $174,000. Finally, Chevy Chase Trust Holdings LLC boosted its stake in shares of MaxCyte by 2,182.6% in the first quarter. Chevy Chase Trust Holdings LLC now owns 1,296,397 shares of the company’s stock valued at $5,432,000 after purchasing an additional 1,239,602 shares during the period. Institutional investors and hedge funds own 68.81% of the company’s stock.

Insider Transactions at MaxCyte

In other MaxCyte news, EVP Thomas M. Ross sold 15,476 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $4.54, for a total transaction of $70,261.04. Following the transaction, the executive vice president now directly owns 25,000 shares in the company, valued at $113,500. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other MaxCyte news, Director Stanley C. Erck sold 29,767 shares of MaxCyte stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.97, for a total value of $118,174.99. Following the completion of the transaction, the director now owns 269,118 shares of the company’s stock, valued at $1,068,398.46. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Thomas M. Ross sold 15,476 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $4.54, for a total transaction of $70,261.04. Following the sale, the executive vice president now directly owns 25,000 shares in the company, valued at $113,500. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 75,850 shares of company stock valued at $307,148. 3.00% of the stock is currently owned by corporate insiders.

MaxCyte Price Performance

MaxCyte stock opened at $3.67 on Thursday. The firm’s fifty day moving average price is $4.08 and its 200 day moving average price is $4.24. The company has a market capitalization of $384.70 million, a price-to-earnings ratio of -10.49 and a beta of 1.39. MaxCyte, Inc. has a 12-month low of $2.80 and a 12-month high of $5.55.

MaxCyte (NASDAQ:MXCT) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.05. MaxCyte had a negative return on equity of 15.52% and a negative net margin of 77.97%. The firm had revenue of $10.43 million during the quarter, compared to the consensus estimate of $8.20 million. During the same quarter in the prior year, the business posted ($0.10) earnings per share. Analysts forecast that MaxCyte, Inc. will post -0.44 earnings per share for the current fiscal year.

MaxCyte Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.